avoplacel (PLX-R18) / Pluri  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avoplacel (PLX-R18) / Pluri
NCT03002519: Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

Completed
1
21
US, RoW
PLX-R18
Pluristem Ltd.
Incomplete HCT (Hematopoietic Cell Transplantation)
09/21
10/21
NCT03797040: Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)

Unknown status
1
27
NA
Cell therapy, PLX-R18
Pluristem Ltd.
Ionizing Radiation Exposure
12/21
12/21

Download Options